13.2 Illinois Compounding Rules & Beyond-Use Dates
Key Takeaways
- Beyond-use dates (BUDs) are assigned using USP <795>/<797> frameworks (and stability data when available)—they are not the same as manufacturer expiration dates on unopened commercial products.
- Commonly tested revised <795> default BUD anchors (without CNSP-specific stability data): non-preserved aqueous forms often max 14 days refrigerated; preserved aqueous up to 35 days; nonaqueous oral liquids up to 90 days—always verify against current official USP and do not invent extra tables.
- Illinois 1330.640 requires patient-specific compounding as the default, detailed office-use rules for limited nonsterile stock, exclusive compounding space, logbooks, 5-year records, special compound labeling language, and temperature-controlled off-site delivery.
- 503A traditional compounding pharmacies prepare for identified patients under state/USP rules; 503B outsourcing facilities register with FDA, follow cGMP, and may compound without patient-specific prescriptions under federal 503B conditions.
- Inspection readiness means producing MFRs/CRs, training files, USP references, equipment/calibration evidence, HD controls if applicable, and proof the sterile area was Department-approved if sterile services were added.
13.2 Illinois Compounding Rules & Beyond-Use Dates
Quick Answer: Assign beyond-use dates (BUDs) with the official USP <795> (nonsterile) and USP <797> (sterile) frameworks—using stability data when available and default maximums when not. Illinois 68 Ill. Adm. Code 1330.640 requires patient-specific compounding as the default, limits office use, mandates equipment/space/records, dictates compound labels (including a required “specifically compounded for you” statement), and holds the PIC to training and sterile add-on inspection duties. Distinguish 503A traditional compounding pharmacies from 503B outsourcing facilities. Be inspection-ready: master formulation records, compounding records, lots/expirations, BUDs, and sterile-area approval.
Section 13.1 taught which standards apply. This section teaches how long compounds may be used, what Illinois operational rules require day to day, and how federal 503A/503B models differ—all high-yield for NABP 4.5 Compounding and related operations items.
Beyond-Use Dates: Framework First, Not Guesswork
BUD vs manufacturer expiration date
| Concept | Applies to | Meaning |
|---|---|---|
| Manufacturer expiration date | Unopened commercial product stored as labeled | Manufacturer-supported shelf life |
| Beyond-use date (BUD) | Compounded preparation (and sometimes opened/manipulated products under other standards) | Date/time after which the compounded preparation should not be stored or used, assigned by the compounder under USP rules |
Never automatically copy a bulk ingredient’s expiration date onto a multi-ingredient aqueous cream and call it a year-long BUD. Water activity, sterility risk, packaging, storage temperature, and process controls drive BUDs.
Nonsterile BUDs under revised USP <795> (teach carefully)
USP revised <795> (official November 1, 2023) uses a water-activity / aqueous vs nonaqueous approach and sets maximum default BUDs when the compounder lacks CNSP-specific stability information. Exact official tables can be updated—exam strategy: know the logic and the commonly tested default anchors from current training materials; if a stem quotes a table, apply the stem; do not invent exotic day counts.
Commonly tested revised <795> default anchors (no CNSP-specific stability data):
| Preparation type (exam language) | Typical default maximum BUD taught on many MPJE/tech banks |
|---|---|
| Non-preserved aqueous dosage form (higher water activity) | 14 days under refrigeration |
| Preserved aqueous dosage form | Up to 35 days (per revised default framework) |
| Nonaqueous oral liquid (low water activity) | Up to 90 days |
| Solid dosage forms (e.g., capsules) and certain nonaqueous topicals | Longer defaults exist in the chapter (often cited up to 180 days for some nonaqueous solids)—still capped by earliest API/excipient expiration and chapter rules |
Rules of thumb that survive vignettes:
- Aqueous + no preservative → short refrigerated BUD (commonly tested 14 days).
- More water / more microbial risk → shorter BUD.
- Stability data specific to the CNSP may support a different BUD within chapter limits—defaults are not a license to ignore data or to exceed chapter maxima.
- BUD cannot exceed the shortest remaining expiration of a component when chapter/logic requires that control.
- Label the BUD clearly; if time-of-day matters clinically (more common with sterile), include time.
Sterile BUDs under USP <797> (category logic)
Revised <797> (also official November 1, 2023) organizes CSPs largely by Category:
| Category identity (exam-level) | Facility / process idea | BUD character |
|---|---|---|
| Category 1 | Often prepared in a segregated compounding area (SCA) or under limited conditions | Shorter BUDs—commonly taught anchors include ≤12 hours controlled room temperature or ≤24 hours refrigerated |
| Category 2 | Prepared in a full cleanroom suite meeting chapter requirements | Longer BUDs possible than Category 1, still constrained by sterility/stability factors |
| Category 3 | Additional requirements (e.g., sterility testing and stricter facility/personnel programs as the chapter specifies) | Potential for extended BUDs versus Category 2 when all conditions met |
| Immediate-use | Emergent, short start-to-administration windows; not a routine batching pathway | Very short use window—not a loophole for anticipatory stock |
Teaching discipline for this guide: memorize Category 1 = shorter, Category 2/3 = longer with stricter controls, and the 12-hour / 24-hour Category 1 room-temp/refrigerated anchors commonly tested. Do not invent a full multi-row sterile BUD table from memory on exam day if you are unsure—use the category framework and any numbers the stem supplies.
Storage and shipment interact with BUD
Illinois 1330.640(e)(9) makes the PIC ensure environmental control of preparations shipped or delivered off-site: compounded pharmaceuticals must travel in temperature-controlled delivery containers as defined by USP standards. A correct BUD on the label is worthless if the product baked in a car trunk.
Illinois Part 1330 Compounding Operations (1330.640 Deep Dive)
Patient-specific default and office-use structure
1330.640(a): A pharmacy may only dispense compounded drugs pursuant to a valid patient-specific prescription, except as provided in the Section.
Nonsterile office use (1330.640(d)) — permitted only when all of the following ideas are satisfied:
- Quantity does not exceed what the practitioner anticipates using before the BUD
- Quantity is reasonable for intended use and nature of the practice
- Quantity for any one practitioner and for all practitioners overall is not greater than what the pharmacy can compound in compliance with USP identity/strength/quality/purity standards
- Records retained ≥ 5 years, readily retrievable, including practitioner identity/contact, date of order, name/strength/qty/dosage form, containers, date compounded, date provided, lot number, and BUD
- Label includes pharmacy name/address/phone; name/strength/dosage form and active ingredients; pharmacy lot and BUD; quantity; ancillary storage/caution/HD warnings; and “For Office Use Only – Not for Resale”
Sterile office use: prohibited unless full 503B + wholesale distributor compliance (1330.640(c)). Patient-specific sterile compounds may still go to the prescriber’s office for administration under a valid patient-specific Rx.
Veterinary exception (1330.640(g)): notwithstanding other provisions of the Section, a pharmacy may compound a reasonable quantity of sterile and nonsterile products for office use by a veterinarian.
Sales limits (1330.640(e)(10)): sales of compounded drugs to other pharmacies not under common ownership, or to clinics, hospitals, or manufacturers, are not allowed except office-use pathways and centralized prescription filling contracts under Section 25.5 of the Act (including anticipatory compounding based on routine, readily observed patterns).
Minimum standards and equipment
Every compounding pharmacy must maintain at least:
- Separate storage area for compounding materials
- Scales/measuring devices with sufficient accuracy
- An area used exclusively for compounding
- Logbook/record system (lots, component expirations, BUDs) for each nonsterile compound and each sterile compound with BUD > 24 hours
- Current USP Compounding Compendium (electronic/internet access OK)
- Veterinary reference if engaged in veterinary compounding (e.g., Plumb’s or Division-approved alternative)
- Appropriate consumables (capsules, ointment jars, distilled water, etc.)
Labeling of compounds dispensed to patients
1330.640(e)(8)(B)–(C) patient-label requirements (permanent label) include, as applicable:
- Pharmacy name, address, telephone (if not used within the facility)
- Date dispensed and identifying number (if used off-site)
- Patient’s name and room number if applicable
- Name of each drug component, strength, amount, dosage form
- Directions for use and/or infusion rate if used off-site
- Prescriber’s name if used off-site
- Required controlled-substance transfer warnings when applicable
- Beyond-use date, and time if appropriate
- Identity of compounding/dispensing pharmacist or authorized individual if used off-site
- Auxiliary storage labels if applicable
- Required statement: “This prescription was specifically compounded in our pharmacy for you at the direction of your prescriber.”
Miss the special compound statement on a vignette and you will lose easy points.
Sterile-specific Illinois add-ons
For sterile compounding, 1330.640(f) adds:
- On-hand law texts (Act/Part 1330, Illinois CSA, 77 Ill. Adm. Code 3100, 21 CFR Food & Drugs, Hypodermic Syringes and Needles Act)—electronic OK
- A compatibility reference (e.g., ASHP Handbook on Injectable Drugs, King’s Guide, or Division-approved alternative)
- File/reference on extended (>24 hours) stability data for finished preparations
- Pharmacist accessible at all times; 24-hour telephone number on labels of compounded drugs and medication infusion devices if used off-site
- Emergency medications appropriate for allergic/common adverse effects when dispensing sterile compounds for off-site facilities or home administration (dispensed upon authorized order)
Ingredients from approved/quality sources
Exam-safe ingredient rules (USP + Illinois integrity themes):
- Prefer USP/NF-grade or other quality-suitable components from FDA-registered establishments when available
- Do not compound from ingredients of unknown identity, strength, quality, or purity
- Do not routinely compound essentially copies of commercially available products without a documented clinical need (federal compounding policy themes)
- Track lot numbers and expiration dates of components into the compounding record (1330.640(e)(4))
- Assign BUDs that respect component dating and USP frameworks
“Amazon mystery powder” is never an acceptable active pharmaceutical ingredient source on an MPJE answer.
503A vs 503B (High-Level Distinction)
| Feature | 503A traditional compounding pharmacy | 503B outsourcing facility |
|---|---|---|
| Core statute | FD&C Act §503A | FD&C Act §503B |
| Patient-specific Rx | Required (pharmacy practice model) | Not required for each unit under 503B model |
| Primary overseers | State board / IDFPR + FDA boundary enforcement | FDA registration/inspection emphasis + state licensure as applicable |
| Quality system identity | USP compounding chapters + state pharmacy rules | cGMP |
| Office stock sterile | Illinois: not via ordinary 503A—needs 503B path (1330.640(c)) | Designed for non-patient-specific compounding under 503B conditions |
| Adverse events / reporting | Standard pharmacy professional/state duties | Explicit FDA adverse-event reporting expectations in the 503B model |
| Wholesale distribution | Generally not a drug wholesaler by compounding alone | Illinois sterile office-use path pairs 503B with wholesale distributor licensure |
Exam sentence to memorize: 503A = patient-specific pharmacy compounding under USP/state rules; 503B = FDA-registered outsourcing facility under cGMP that may compound without patient-specific prescriptions.
Inspection Readiness for Compounding Areas
IDFPR investigators and annual self-inspection (1330.800) both expect compounding sites to prove control—not merely claim “we follow USP.”
Ready-to-produce packet
- Pharmacy license reflecting current services; documentation of Department inspection/approval if sterile compounding was added after initial licensure (1330.640(i))
- Policies/procedures for nonsterile, sterile, and hazardous-drug workflows as applicable
- Master formulation records and compounding records with component lots, expirations, BUDs, and identities of compounders/verifiers
- Training/competency files for every pharmacist, student pharmacist, and technician who compounds (1330.640(h))—current and specific to the dosage forms/risks
- USP Compounding Compendium access and sterile compatibility/stability references
- Equipment logs (balances, PECs certification concepts, temperature monitoring for refrigerators/freezers used for compounds)
- Environmental control evidence for off-site deliveries (temperature-controlled containers, shipping SOPs)
- Office-use logs if nonsterile office-use or veterinary office-use is performed
- Hazardous-drug list, PPE inventory, spill kits, containment equipment, and waste procedures if HDs are handled
- Patient profiles and 5-year readily retrievable audit trails (1330.640(e)(8)(D))
Common inspection failures (and MPJE traps)
| Finding | Why it fails |
|---|---|
| Compounding on the counseling counter next to food/drinks | No exclusive compounding area; sanitary/control failure |
| No BUD or wrong BUD for aqueous non-preserved liquid | USP <795> framework ignored |
| Sterile prep without approved area / no PEC | <797> + 1330.640(i) failure |
| Missing “specifically compounded for you” label statement | 1330.640 labeling violation |
| Selling sterile non-patient-specific stock to clinics | 1330.640(c) / 503A boundary violation |
| Training “done verbally years ago,” no documentation | 1330.640(h) documentation failure |
| Cannot produce lot numbers of ingredients for last month’s batch | Logbook/audit-trail failure |
Worked Vignettes
Vignette 1 — BUD. Pharmacist compounds a non-preserved aqueous oral liquid without stability studies and assigns a 6-month room-temperature BUD. Problem: revised <795> default logic points to a short refrigerated BUD (commonly 14 days), not months at room temperature.
Vignette 2 — Office-use label. Nonsterile office-use jar leaves the pharmacy labeled only with drug name and pharmacy phone, no “For Office Use Only – Not for Resale,” no BUD. Violation of 1330.640(d)(5).
Vignette 3 — 503A vs 503B. Medical office wants weekly non-patient-specific sterile irrigation stock from a community pharmacy that is not a 503B facility. Refuse under 1330.640(c); discuss patient-specific prescriptions or a lawful outsourcing facility source.
Vignette 4 — Inspection. Investigator asks for sterile compounding training files; PIC says “everyone trained themselves on YouTube.” Failure of documented adequate training under 1330.640(h).
Vignette 5 — Central fill anticipatory. Two commonly owned pharmacies under a Section 25.5 central-fill arrangement compound a modest anticipatory quantity of a nonsterile preparation based on routine demand. Potentially lawful under the anticipatory/central-fill pathway—contrast with open-market sales to unaffiliated clinics.
Study Checklist
- BUD ≠ manufacturer expiration; use <795>/<797> frameworks and stability data.
- Memorize high-yield nonsterile default anchors (14-day refrigerated non-preserved aqueous; 35-day preserved aqueous; 90-day nonaqueous oral liquid) and Category 1 sterile short BUDs (12h RT / 24h fridge anchors).
- Illinois default: patient-specific Rx; know nonsterile office-use vs sterile office-use ban without 503B+wholesale path.
- Labels: components, BUD, and “specifically compounded for you…” statement; office-use jars need “For Office Use Only – Not for Resale.”
- Records: lots, expirations, BUDs, 5 years, MFR + CR.
- 503A patient-specific USP/state model vs 503B FDA/cGMP outsourcing model.
- Inspection day: training files, approved sterile area, temperature-controlled shipping, exclusive compounding space.
Master BUDs and 1330.640 operations and you convert compounding from abstract USP chapter numbers into the decision rules Illinois MPJE items actually test—completing Area 4’s compounding strand before final test-day strategy in Chapter 14.
Under the revised USP <795> framework commonly tested on the MPJE, what is the maximum default BUD for a non-preserved aqueous dosage form without CNSP-specific stability data?
Which statement best distinguishes a 503A traditional compounding pharmacy from a 503B outsourcing facility?
In addition to standard Pharmacy Practice Act labeling elements, Illinois 1330.640 requires compounded drugs dispensed to patients to include which statement on the label or an auxiliary label?
Under USP <797> exam-level category logic, Category 1 compounded sterile preparations are best described as: